GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Operating Income

Biovica International AB (OSTO:BIOVIC B) Operating Income : kr-107.77 Mil (TTM As of Jan. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Operating Income?

Biovica International AB's Operating Income for the three months ended in Jan. 2025 was kr-22.27 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2025 was kr-107.77 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Biovica International AB's Operating Income for the three months ended in Jan. 2025 was kr-22.27 Mil. Biovica International AB's Revenue for the three months ended in Jan. 2025 was kr2.26 Mil. Therefore, Biovica International AB's Operating Margin % for the quarter that ended in Jan. 2025 was -984.92%.

Warning Sign:

Biovica International AB operating margin has been in a 5-year decline. The average rate of decline per year is -20.7%.

Biovica International AB's 5-Year average Growth Rate for Operating Margin % was -20.70% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Biovica International AB's annualized ROC % for the quarter that ended in Jan. 2025 was -177.24%. Biovica International AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 was -1,355.80%.


Biovica International AB Operating Income Historical Data

The historical data trend for Biovica International AB's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Operating Income Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -29.82 -41.58 -61.30 -110.92 -127.63

Biovica International AB Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.92 -41.61 -23.56 -20.34 -22.27

Biovica International AB Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-107.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Biovica International AB's annualized ROC % for the quarter that ended in Jan. 2025 is calculated as:

ROC % (Q: Jan. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2024 ) + Invested Capital (Q: Jan. 2025 ))/ count )
=-89.076 * ( 1 - -3.61% )/( (52.262 + 51.881)/ 2 )
=-92.2916436/52.0715
=-177.24 %

where

Note: The Operating Income data used here is four times the quarterly (Jan. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Biovica International AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2024  Q: Jan. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-89.076/( ( (6.893 + max(-9.631, 0)) + (6.247 + max(-11.023, 0)) )/ 2 )
=-89.076/( ( 6.893 + 6.247 )/ 2 )
=-89.076/6.57
=-1,355.80 %

where Working Capital is:

Working Capital(Q: Oct. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.372 + 2.077 + 0) - (3.58 + 0 + 9.5)
=-9.631

Working Capital(Q: Jan. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.801 + 1.704 + 0) - (3.504 + 0 + 11.024)
=-11.023

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Biovica International AB's Operating Margin % for the quarter that ended in Jan. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2025 )/Revenue (Q: Jan. 2025 )
=-22.269/2.261
=-984.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biovica International AB Operating Income Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB Business Description

Traded in Other Exchanges
N/A
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. The company develops and commercializes blood-based diagnostic tests with biomarkers that improve the monitoring and evaluation of modern cancer treatments. The company promotes healthcare through collaboration with cancer institutes and pharmaceutical companies. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB Headlines

No Headlines